STOCK TITAN
  1. Home
  2. Sec-filings
  3. MYNZ
  4. [Form 3] MAINZ BIOMED N.V. Initial Statement of Beneficial Ownership

Mainz Biomed (MYNZ) CEO discloses share and option holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Mainz Biomed N.V. filed an initial Form 3 showing Chief Executive Officer and director Guido Baechler’s beneficial ownership in the company’s securities as of 01/01/2026. He directly holds 6,362 ordinary shares.

Baechler also holds several employee stock options. One grant covers 145,000 ordinary shares at an exercise price of $4.95, with 50% vested on 03/04/2025 and the remaining 25% portions scheduled to vest on 03/24/2026 and 03/04/2027. A second grant for 11,696 ordinary shares at $200 per share is fully vested. A third grant for 2,000 ordinary shares at $302.8 per share vests over four years, with 25% vesting on 12/21/2023 and the remainder vesting monthly through 12/21/2026.

Positive

  • None.

Negative

  • None.
Insider BAECHLER GUIDO
Role Chief Executive Officer
Type Security Shares Price Value
holding Employee Stock Option (Right to Buy) -- -- --
holding Employee Stock Option (Right to Buy) -- -- --
holding Employee Stock Option (Right to Buy) -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: Employee Stock Option (Right to Buy) — 158,696 shares (Direct); Ordinary Shares — 6,362 shares (Direct)
Footnotes (3)
  1. F1. 50% of the option vested upon grant on 03/04/2025; the remaining balance vests 25% on 03/24/26 and 25% on 03/04/2027.
  2. F2. Fully vested.
  3. F3. Four-year vesting schedule: 25% vests on 12/21/2023, and the remainder vests 1/36 per month until 12/21/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →

FAQ

What does Mainz Biomed (MYNZ) CEO Guido Baechler report on this Form 3?

The Form 3 shows that Chief Executive Officer and director Guido Baechler beneficially owns 6,362 ordinary shares of Mainz Biomed N.V. and several employee stock option grants over additional ordinary shares.

How many Mainz Biomed ordinary shares does the CEO directly own according to the filing?

According to the filing, Guido Baechler directly owns 6,362 ordinary shares of Mainz Biomed N.V.

What stock option grants does the Mainz Biomed CEO hold?

The CEO holds three employee stock option grants: one for 145,000 ordinary shares at $4.95 per share, one for 11,696 ordinary shares at $200 per share, and one for 2,000 ordinary shares at $302.8 per share.

What is the vesting schedule for the 145,000-share stock option at $4.95?

For the 145,000-share option at $4.95, 50% vested on 03/04/2025; the remaining balance vests 25% on 03/24/2026 and 25% on 03/04/2027.

Is the 11,696-share Mainz Biomed stock option fully vested?

Yes. The filing states that the employee stock option covering 11,696 ordinary shares at an exercise price of $200 per share is fully vested.

How does the four-year vesting schedule work for the 2,000-share option at $302.8?

The 2,000-share option at $302.8 per share vests over four years: 25% vested on 12/21/2023, and the remaining shares vest in equal monthly installments (1/36 per month) until 12/21/2026.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
BAECHLER GUIDO
(Last) (First) (Middle)
MAINZ BIOMED N.V.
ROBERT KOCH STRASSE 50
(Street)
MAINZ 2M 55129
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2026 		3. Issuer Name and Ticker or Trading Symbol
MAINZ BIOMED N.V. [ MYNZ ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares 6,362 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) 03/04/2025 (1) Ordinary Shares 145,000 $4.95 D
Employee Stock Option (Right to Buy) 11/04/2021 (2) Ordinary Shares 11,696 $200 D
Employee Stock Option (Right to Buy) 12/21/2022 (3) Ordinary Shares 2,000 $302.8 D
Explanation of Responses:
1. 50% of the option vested upon grant on 03/04/2025; the remaining balance vests 25% on 03/24/26 and 25% on 03/04/2027.
2. Fully vested.
3. Four-year vesting schedule: 25% vests on 12/21/2023, and the remainder vests 1/36 per month until 12/21/2026.
/s/ Guido Baechler 01/26/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR